Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CMV Infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: CMV Infection. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2020-005582-13 Sponsor Protocol Number: CHUBX2020/26 Start Date*: 2021-03-03
    Sponsor Name:CHU de Bordeaux
    Full Title: Prospective pilot study evaluating a therapeutic synergy between the infusion of CMV-specific immunoglobulins and the level before transplantation of negative gamma delta Vdelta 2 T lymphocytes exp...
    Medical condition: CMV infection in transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024307-27 Sponsor Protocol Number: LUMC2010-03 Start Date*: 2011-11-01
    Sponsor Name:Leiden University Medical Center
    Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Medical condition: CMV reactivation after allogeneic stem cell transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022514-47 Sponsor Protocol Number: NV25409 Start Date*: 2011-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
    Medical condition: Treatment and prevention of CMV disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10049107 CMV viraemia LLT
    16.0 100000004862 10009703 CMV infection LLT
    16.0 100000004848 10009701 CMV LLT
    16.0 100000004862 10060577 CMV viremia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002311-26 Sponsor Protocol Number: INMUNOCELL Start Date*: 2021-12-09
    Sponsor Name:IDIVAL
    Full Title: PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN haploidentical PROGENITORS HEMATOPOIETIC TRANSPLANTATIONWITH ADOPTIVE CELL IMMUNOTHERAPY.
    Medical condition: Primary prophylaxis of CMV infection in haploidentical transplantation of hematopoietic progenitors.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10025309 Haematological and lymphoid tissue therapeutic procedures HLGT
    21.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    22.0 10042613 - Surgical and medical procedures 10067859 Allogenic stem cell transplantation PT
    20.0 100000004862 10011827 Cytomegaloviral infections HLT
    20.0 100000004848 10025263 Lymphocytes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002374-82 Sponsor Protocol Number: TAK-620-3001 Start Date*: 2022-11-21
    Sponsor Name:Takeda
    Full Title: A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoie...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003831-31 Sponsor Protocol Number: 8228-001 Start Date*: 2014-04-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infect...
    Medical condition: Clinically significant CMV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) IT (Completed) FI (Completed) AT (Completed) ES (Completed) BE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004692-19 Sponsor Protocol Number: 963 Start Date*: 2007-12-19
    Sponsor Name:Biotest AG
    Full Title: Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study...
    Medical condition: Congenital CMV infection after primary CMV infection during pregnancy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10010420 Congenital CMV infection LLT
    Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002245-37 Sponsor Protocol Number: GV28418 Start Date*: 2013-01-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS
    Medical condition: Transplant-associated cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021881 - Infections and infestations 10058881 Cytomegalovirus viremia LLT
    15.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    15.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    15.0 10021881 - Infections and infestations 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006146-34 Sponsor Protocol Number: 100505 Start Date*: 2008-04-30
    Sponsor Name:Stage Pharmaceuticals GmbH
    Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial
    Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004698-30 Sponsor Protocol Number: 2020-42 Start Date*: 2021-06-30
    Sponsor Name: CHU de Lille
    Full Title: Efficacy and Safety of Cytotect®CP, hyperimmune anti-CMV IVIg as CMV prophylaxis in patients developing acute grade II-IV GVHD after allogeneic hematopoietic cell transplantation A prospective phas...
    Medical condition: Post-transplant human cytomegalovirus (CMV) infection is a challenge in patients receiving allogeneic hematopoietic cell transplants (allo-HCT) due to severe immunosuppression. In the absence of t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001545-20 Sponsor Protocol Number: mRNA-1647-P104 Start Date*: 2024-05-09
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age...
    Medical condition: Cytomegalovirus infection
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-004795-35 Sponsor Protocol Number: CMX001-301 Start Date*: 2014-06-02
    Sponsor Name:Chimerix, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection ...
    Medical condition: Cytomegalovirus (CMV) Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002556-39 Sponsor Protocol Number: 2020/0422/HP Start Date*: 2022-11-28
    Sponsor Name:DRCI - CHU de Rouen
    Full Title: Efficacy of a preventive strategy for immuno-guided cytomegalovirus infection compared to a universal prophylactic strategy in renal transplant recipients
    Medical condition: Patients receiving a kidney transplant (1 to 12 days post-transplant)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002603-15 Sponsor Protocol Number: GANCMV-2011 Start Date*: 2011-11-21
    Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA
    Full Title: Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Medical condition: Active infection with cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006649-18 Sponsor Protocol Number: 08/0214 Start Date*: 2011-11-16
    Sponsor Name:University College London
    Full Title: CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell ...
    Medical condition: CMV reactivation/infection in post allogeneic haematopoietic stem cell transplant recipients. Allo-HSCT being performed for underlying haematological malignancy (eg, AML, ALL, NHL, Hodgkin Lymphoma...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001515-22 Sponsor Protocol Number: S54226 Start Date*: 2012-05-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: Cytomegalovirus infection and the influenza vaccination response in older persons
    Medical condition: Humoral and cellular immune response after vaccination in older people
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002232-41 Sponsor Protocol Number: P140310 Start Date*: 2015-11-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010420 Congenital CMV infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021433-32 Sponsor Protocol Number: GCV2010 Start Date*: 2011-03-29
    Sponsor Name:INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE(IDIBELL)
    Full Title: Individualización de las dosis de Ganciclovir/Valganciclovir por predicción bayesiana en pacientes trasplantados de órgano sólido infectados por citomegalovirus
    Medical condition: Enfermedad por citomegalovirus en trasplante de órgano sólido
    Disease: Version SOC Term Classification Code Term Level
    13 10011836 Infección por citomegalovirus LLT
    13 10058854 Viremia por citomegalovirus PT
    13 10011827 Infecciones por citomegalovirus HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 07:47:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA